# Therapeutic Strategy Associated With bDMARDs or tsDMARDs in Rheumatoid Arthritis and Psoriatic Arthritis

> **NCT05082805** · — · UNKNOWN · sponsor: **Nordic Pharma SAS** · enrollment: 400 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Psoriatic Arthritis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05082805
- **Lead sponsor:** Nordic Pharma SAS
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-25
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2021-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05082805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05082805, "Therapeutic Strategy Associated With bDMARDs or tsDMARDs in Rheumatoid Arthritis and Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05082805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*